Vascular Biogenics Ltd. (VBLT) Sees Large Volume Increase
Vascular Biogenics Ltd. (NASDAQ:VBLT) saw an uptick in trading volume on Thursday . 1,163,139 shares traded hands during trading, an increase of 424% from the previous session’s volume of 221,803 shares.The stock last traded at $4.27 and had previously closed at $4.01.
A number of brokerages have issued reports on VBLT. Chardan Capital restated a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Piper Jaffray Cos. restated a “buy” rating and set a $14.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Roth Capital restated a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a research report on Thursday, June 9th. Zacks Investment Research upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 15th. Finally, HC Wainwright began coverage on Vascular Biogenics in a research note on Tuesday, June 28th. They set a “buy” rating and a $11.00 target price on the stock. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Vascular Biogenics has an average rating of “Buy” and a consensus target price of $13.67.
The stock’s market cap is $96.06 million. The stock has a 50-day moving average of $4.08 and a 200 day moving average of $3.74.
Vascular Biogenics (NASDAQ:VBLT) last posted its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.09. Equities analysts expect that Vascular Biogenics Ltd. will post ($0.64) EPS for the current year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.